In recent years, with accelerating population aging and changes in lifestyle, the prevalence of chronic diseases such as hypertension, diabetes, and coronary artery disease has continued to rise. As one of the most important risk factors for atherosclerotic cardiovascular disease (ASCVD), dyslipidemia has become a central focus of chronic disease management.

Extensive research has confirmed that elevated low-density lipoprotein cholesterol (LDL-C) is closely associated with the risk of myocardial infarction, stroke, and peripheral arterial disease. Therefore, how to scientifically select lipid-lowering medications, develop individualized treatment strategies, and maintain long-term management has become an essential component of modern chronic disease prevention and treatment.

As lipid-lowering therapies continue to evolve, lipid management has gradually expanded beyond statins alone to include cholesterol absorption inhibitors, PCSK9 inhibitors, RNA-based therapies, and various treatment options targeting triglyceride abnormalities. For patients with different risk profiles and lipid patterns, treatment selection is becoming increasingly precise and personalized.

---

Why Does Dyslipidemia Require Long-Term Management?

Dyslipidemia typically presents as:

• Elevated low-density lipoprotein cholesterol (LDL-C)
• Elevated total cholesterol (TC)
• Elevated triglycerides (TG)
• Reduced high-density lipoprotein cholesterol (HDL-C)

Among these, LDL-C is considered one of the most important contributors to atherosclerosis.

Because elevated lipid levels often produce no obvious symptoms, many patients are not diagnosed until they experience myocardial infarction, stroke, or severe coronary artery stenosis. As a result, modern clinical guidelines emphasize early screening, early intervention, and long-term management.

Patients with the following conditions generally require more aggressive lipid-lowering strategies:

• Coronary artery disease
• History of myocardial infarction
• Ischemic stroke
• Diabetes with cardiovascular risk factors
• Familial hypercholesterolemia

---

Statins: The Cornerstone of Lipid Management

Over the past several decades of clinical practice, statins have remained the foundation of dyslipidemia treatment and continue to be the most extensively studied and widely used lipid-lowering medications.

Their primary mechanism of action involves inhibiting HMG-CoA reductase, the key enzyme responsible for cholesterol synthesis. This reduces hepatic cholesterol production while increasing LDL receptor expression on liver cells, thereby enhancing the clearance of LDL-C from the bloodstream.

Beyond lowering cholesterol levels, statins also help:

• Stabilize atherosclerotic plaques
• Improve endothelial function
• Reduce vascular inflammation

These additional benefits are believed to contribute significantly to their ability to reduce cardiovascular events.

Current international guidelines recommend statins as the first-line therapy for both primary and secondary prevention of ASCVD. For most patients, appropriate statin use and long-term adherence remain among the most effective strategies for reducing cardiovascular risk.

---

PCSK9 Inhibitors: A Major Breakthrough for High-Risk Patients

In recent years, PCSK9 inhibitors have emerged as one of the most significant innovations in lipid management.

Representative agents include:

• Alirocumab
• Evolocumab

PCSK9 promotes the degradation of LDL receptors, while PCSK9 inhibitors block this process, allowing more LDL receptors to remain on the surface of liver cells and continuously remove LDL cholesterol from circulation.

Clinical studies have shown that these therapies can:

• Further reduce LDL-C by more than 50%–60%
• Lower the risk of cardiovascular events
• Benefit patients with very high-risk ASCVD
• Benefit patients with familial hypercholesterolemia

For patients who fail to achieve lipid targets with conventional therapies, PCSK9 inhibitors have become an important treatment option.

---

siRNA Lipid-Lowering Therapies: A New Direction in Long-Acting Cholesterol Management

Unlike conventional medications that act directly on proteins, RNA-based therapies regulate gene expression and reduce the production of disease-related proteins at their source. Among these approaches, small interfering RNA (siRNA) therapies targeting PCSK9 have become one of the most promising innovations in lipid management.

These therapies use liver-targeted delivery systems that enable selective uptake by hepatocytes, where they suppress PCSK9 protein synthesis and thereby achieve sustained reductions in LDL-C levels.

One of the most significant advantages of RNA therapies is their long duration of action. Some treatment regimens require only a few doses per year to maintain stable lipid control, which may be particularly beneficial for patients requiring lifelong therapy.

Medication adherence has long been a challenge in chronic disease management. Long-acting treatment strategies may help reduce missed doses and treatment discontinuation, ultimately improving long-term outcomes.

Although these therapies are still expanding globally, they represent an important milestone in precision lipid management and continue to reshape the future treatment landscape for dyslipidemia.

---

How Should Medications Be Selected for Patients with Elevated Triglycerides?

Not all cases of dyslipidemia are primarily characterized by elevated LDL-C. In public perception, dyslipidemia is often equated with high cholesterol, but elevated triglycerides (TG) also have important clinical implications.

Significantly elevated triglyceride levels may not only increase the risk of atherosclerotic cardiovascular disease but can also contribute to serious complications such as acute pancreatitis.

For these patients, treatment goals extend beyond lowering LDL-C and include targeted management of triglyceride abnormalities.

Lifestyle interventions remain the cornerstone of treatment and include:

• Weight management
• Reducing refined carbohydrate intake
• Limiting alcohol consumption
• Increasing physical activity

When lifestyle modifications alone are insufficient, clinicians may recommend triglyceride-lowering medications according to each patient’s overall cardiovascular risk and lipid profile.

Depending on the individual clinical situation, treatment options may include:

• Fibrates
• Prescription omega-3 fatty acids
• Combination lipid-lowering therapies

Therefore, dyslipidemia management should never focus on a single laboratory value. Instead, clinicians should formulate individualized treatment plans based on each patient’s complete lipid profile, cardiovascular risk, comorbidities, and long-term treatment goals.

---

Individualized Lipid Management Is Becoming the Standard of Care

As our understanding of lipid metabolism continues to improve, treatment strategies have shifted from a “one-size-fits-all” approach toward personalized medicine.

Today’s clinicians consider multiple factors when selecting lipid-lowering therapies, including:

• Baseline LDL-C level
• Overall ASCVD risk
• Previous cardiovascular events
• Presence of diabetes
• Familial hypercholesterolemia
• Medication tolerance
• Patient adherence
• Treatment accessibility

For many patients, statin monotherapy remains sufficient to achieve recommended LDL-C targets.

However, for patients at very high cardiovascular risk or those who cannot achieve target lipid levels with statins alone, combination therapy may provide additional benefit. This may involve adding cholesterol absorption inhibitors, PCSK9 inhibitors, or newer RNA-based therapies depending on individual clinical circumstances.

The ultimate goal is no longer simply lowering cholesterol numbers but reducing long-term cardiovascular events while maintaining good quality of life.

---

Conclusion

As evidence from clinical research continues to accumulate, dyslipidemia treatment has evolved into a comprehensive therapeutic framework ranging from statins and PCSK9 inhibitors to siRNA-based therapies. For most patients, statins remain the cornerstone of treatment, while innovative lipid-lowering therapies are providing additional options for individuals with very high cardiovascular risk, familial hypercholesterolemia, or inadequate response to conventional treatment.

At the same time, chronic disease management involves far more than selecting advanced medications. Long-term follow-up, regular lipid monitoring, healthy lifestyle interventions, and ongoing cardiovascular risk control remain equally important. Sustainable disease management requires continuous collaboration between patients and healthcare professionals to achieve optimal long-term outcomes.

For some innovative lipid-lowering therapies that are not yet widely accessible in certain regions, patients may benefit from consulting qualified healthcare professionals to learn about the latest international treatment developments, clinical evidence, and medication availability.

As a professional platform dedicated to global innovative medicines and chronic disease management, DengYueMed continues to monitor developments in cardiovascular diseases, metabolic disorders, and next-generation lipid-lowering therapies. Through medication information services, international pharmaceutical consultations, drug source verification, and compliant access pathway support, DengYueMed helps healthcare professionals and patients stay informed about emerging treatment options and advances in lipid management.

As precision medicine continues to evolve, lipid management is expected to become increasingly personalized. Advances in targeted therapies, RNA-based medicines, and long-acting treatment strategies are expanding therapeutic possibilities for patients with dyslipidemia and helping further reduce the global burden of cardiovascular disease.

---

Key Takeaways

• Dyslipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Statins remain the first-line therapy for lowering LDL-C and reducing cardiovascular events.
• PCSK9 inhibitors offer substantial LDL-C reduction for patients at very high cardiovascular risk or those with familial hypercholesterolemia.
• siRNA therapies represent an emerging long-acting treatment strategy that may improve medication adherence.
• Patients with elevated triglycerides require individualized management beyond LDL-C reduction alone.
• Personalized treatment strategies that combine lifestyle modification with appropriate pharmacotherapy are becoming the standard approach to chronic disease management.